These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 25541709)

  • 1. Progressive decrease in the potential usefulness of meningococcal serogroup B vaccine (4CMenB, Bexsero®) in Gipuzkoa, Northern Spain.
    Pérez-Trallero E; Esnal O; Marimón JM
    PLoS One; 2014; 9(12):e116024. PubMed ID: 25541709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B
    Mulhall RM; Bennett D; Cunney R; Borrow R; Lucidarme J; Findlow J; Jolley KA; Bray J; Maiden MCJ; Moschioni M; Serino L; Stella M; Medini D
    mSphere; 2018 Aug; 3(4):. PubMed ID: 30135218
    [No Abstract]   [Full Text] [Related]  

  • 3. Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB).
    Bettinger JA; Scheifele DW; Halperin SA; Vaudry W; Findlow J; Borrow R; Medini D; Tsang R;
    Vaccine; 2013 Dec; 32(1):124-30. PubMed ID: 23588089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicted Strain Coverage of a New Meningococcal Multicomponent Vaccine (4CMenB) in Spain: Analysis of the Differences with Other European Countries.
    Abad R; Medina V; Stella M; Boccadifuoco G; Comanducci M; Bambini S; Muzzi A; Vázquez JA
    PLoS One; 2016; 11(3):e0150721. PubMed ID: 26950303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of invasive Neisseria meningitidis strains from Québec, Canada, during a period of increased serogroup B disease, 2009-2013: phenotyping and genotyping with special emphasis on the non-carbohydrate protein vaccine targets.
    Law DK; Lefebvre B; Gilca R; Deng S; Zhou J; De Wals P; Tsang RS
    BMC Microbiol; 2015 Jul; 15():143. PubMed ID: 26204985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic variability of Polish serogroup B meningococci (2010-2016) including the 4CMenB vaccine component genes.
    Waśko I; Gołębiewska A; Kiedrowska M; Ronkiewicz P; Wróbel-Pawelczyk I; Kuch A; Hong E; Skoczyńska A
    Vaccine; 2020 Feb; 38(8):1943-1952. PubMed ID: 31980191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba®).
    Gandhi A; Balmer P; York LJ
    Postgrad Med; 2016 Aug; 128(6):548-56. PubMed ID: 27467048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distribution of Bexsero® Antigen Sequence Types (BASTs) in invasive meningococcal disease isolates: Implications for immunisation.
    Brehony C; Rodrigues CMC; Borrow R; Smith A; Cunney R; Moxon ER; Maiden MCJ
    Vaccine; 2016 Sep; 34(39):4690-4697. PubMed ID: 27521232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High predicted strain coverage by the multicomponent meningococcal serogroup B vaccine (4CMenB) in Poland.
    Waśko I; Hong E; De Paola R; Stella M; Moschioni M; Taha MK; Skoczyńska A
    Vaccine; 2016 Jan; 34(4):510-515. PubMed ID: 26686998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study.
    Perrett KP; McVernon J; Richmond PC; Marshall H; Nissen M; August A; Percell S; Toneatto D; Nolan T
    Vaccine; 2015 Sep; 33(39):5217-24. PubMed ID: 26232542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variability of genes encoding surface proteins used as vaccine antigens in meningococcal endemic and epidemic strain panels from Norway.
    Holst J; Comanducci M; Bambini S; Muzzi A; Comandi S; Oksnes J; DeTora L; Pizza M; Rappuoli R; Caugant DA
    Vaccine; 2014 May; 32(23):2722-31. PubMed ID: 24631075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccines against Neisseria meningitidis serogroup B strains - What does genomics reveal on the Portuguese strain's coverage.
    Bettencourt C; Nogueira P; Paulo Gomes J; João Simões M
    Vaccine; 2022 Aug; 40(33):4772-4779. PubMed ID: 35778280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Development of a Vaccine Against Meningococcus B Using Reverse Vaccinology.
    Masignani V; Pizza M; Moxon ER
    Front Immunol; 2019; 10():751. PubMed ID: 31040844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Sequencing analysis of the antigens included in the four-component  vaccine against serogroup B meningococcus in Czech isolates of Neisseria meningitidis from 2007-2013].
    Křížová P; Musílek M; Vacková Z; Bečvářová Z; Kozáková J
    Epidemiol Mikrobiol Imunol; 2014 Feb; 63(1):61-8. PubMed ID: 24730996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-reactivity of 4CMenB vaccine-induced antibodies against meningococci belonging to non-B serogroups in Italy.
    Fazio C; Biolchi A; Neri A; Tomei S; Vacca P; Ambrosio L; Palmieri A; Mori E; La Gaetana R; Pizza M; Giuliani MM; Serino L; Stefanelli P
    Hum Vaccin Immunother; 2021 Jul; 17(7):2225-2231. PubMed ID: 33522380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Culture-Confirmed Invasive Meningococcal Disease in Canada, 2010 to 2014: Characterization of Serogroup B
    Tsang RSW; Law DKS; De Paola R; Giuliani M; Stella M; Zhou J; Deng S; Boccadifuoco G; Giuliani MM; Serino L
    mSphere; 2020 Mar; 5(2):. PubMed ID: 32132156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic distribution of noncapsular meningococcal group B vaccine antigens in Neisseria lactamica.
    Lucidarme J; Gilchrist S; Newbold LS; Gray SJ; Kaczmarski EB; Richardson L; Bennett JS; Maiden MC; Findlow J; Borrow R
    Clin Vaccine Immunol; 2013 Sep; 20(9):1360-9. PubMed ID: 23803905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outbreaks of meningococcal B infection and the 4CMenB vaccine: historical and future perspectives.
    Whelan J; Bambini S; Biolchi A; Brunelli B; Robert-Du Ry van Beest Holle M
    Expert Rev Vaccines; 2015 May; 14(5):713-36. PubMed ID: 25603916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine.
    Lucidarme J; Comanducci M; Findlow J; Gray SJ; Kaczmarski EB; Guiver M; Vallely PJ; Oster P; Pizza M; Bambini S; Muzzi A; Borrow R
    Clin Vaccine Immunol; 2010 Jun; 17(6):919-29. PubMed ID: 20375242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular characterization of a collection of Neisseria meningitidis isolates from Croatia, June 2009 to January 2014.
    Bukovski S; Vacca P; Anselmo A; Knezovic I; Fazio C; Neri A; Ciammaruconi A; Fortunato A; Palozzi AM; Fillo S; Lista F; Stefanelli P
    J Med Microbiol; 2016 Sep; 65(9):1013-1019. PubMed ID: 27452726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.